News & Updates
Filter by Specialty:
ARANOTE: Darolutamide positively impacts HRQoL in men with mHSPC
Darolutamide demonstrated clinically meaningful delays in pain progression and deterioration of important patient-relevant health-related quality of life (HRQoL) outcomes vs placebo in men with metastatic hormone-sensitive prostate cancer (mHSPC), according to phase III ARANOTE trial findings presented at ASCO 2025. [ASCO 2025, abstract 5004]
ARANOTE: Darolutamide positively impacts HRQoL in men with mHSPC
24 Jun 2025
BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines
A retrospective cohort study of >11,000 Hong Kong patients who initiated anthracycline-based chemotherapy found that both body-mass index (BMI) and glycaemic status significantly affect cardiovascular (CV) risks, with the highest risk observed in those with concurrent obesity and diabetes/prediabetes.
BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines
24 Jun 2025
Ultrasensitive ctDNA detection predicts breast cancer relapse
A molecular residual disease (MRD) assay powered by whole genome sequencing (WGS) successfully detects breast cancer relapse, improving lead times for circulating tumour DNA (ctDNA) detection years ahead of clinical recurrence based on imaging.
